## ICMJE DISCLOSURE FORM

Date:	.10 <sup>th</sup> February 2022	
Your Name	:Farkhad Manapov	
Manuscrip	: Title: NICOLAS, DETERRED and KEYNOTE 799: Focus on escalation of conventionally fractionat	ed
chemorad	otherapy by immune checkpoint inhibition in unresectable stage III NSCLC	_
Manuscrip	number (if known): TLCR-21-950	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca	Unrestricted Research Institutional Grant from AstraZeneca outside of the mentioned manuscript
3	Royalties or licenses	None	
4	Consulting fees	None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy  Astrazeneca  AstraZeneca  Honoraria: AstraZeneca  Honoraria: Novartis Roche Honoraria: Roche Honoraria: Brainlab Honoraria: Brainlab Honoraria: Brainlab Advisory Board Novartis Advisory Board Novartis Advisory Board Novartis  None  None  None  None  None None None				
lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy  Novartis  Honoraria: Novartis Honoraria: Novartis Honoraria: Novartis Honoraria: Novartis Honoraria: Novartis Advisory Board Honoraria: Lilly Elekta Honoraria: Lilly Advisory Board Novartis Advisory Board Novartis Advisory Board Novartis Novartis Novartis Novartis None Indicate Honoraria: Novartis None None Indicate Honoraria: Novartis Novartis Novartis None Indicate Honoraria: Novartis Novartis Novartis Novartis None Indicate Honoraria: Novartis Novartis Novartis Novartis None Indicate Honoraria: Novartis Novartis Novartis None Indicate Honoraria: Novartis Novartis None Indicate Honoraria: Novartis Novartis None Indicate Honoraria: Novartis Novartis Novartis None Indicate Honoraria: Novartis None Indicate Honoraria: Lilly Elekta Honoraria: Novartis				
speakers bureaus, manuscript writing or educational events  Elekta Brainlab  Honoraria: Elekta Brainlab  Honoraria: Brainlab  Fayment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy  Roche Lilly Honoraria: Roche Honoraria: Coche Honoraria: Lilly Honoraria: Coche Honoraria: Coche Honoraria: Coche Honoraria: Lilly Honoraria: Coche Honoraria: Lilly Honoraria: Brainlab Honoraria: Brainlab Advisory Board Novartis  Advisory Board Novartis Honoraria: Brainlab Honoraria:	5	Payment or honoraria for	AstraZeneca	Honoraria: AstraZeneca
manuscript writing or educational events    Elekta		lectures, presentations,	Novartis	Honoraria: Novartis
educational events  Elekta Brainlab Honoraria: Elekta Brainlab Honoraria: Brainlab  Advisory Board Novartis AstraZeneca Advisory Boards AstraZeneca  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy  Elekta Honoraria: Elekta Honoraria: Elekta Brainlab Honoraria: Elekta Honoraria: Elekta Brainlab Honoraria: Brainlab Advisory Board Novartis Advisory		speakers bureaus,	Roche	Honoraria: Roche
Brainlab Honoraria: Brainlab  6 Payment for expert testimony AstraZeneca Advisory Board Novartis  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy		manuscript writing or	Lilly	Honoraria: Lilly
Restimony   Novartis   Advisory Board Novartis		educational events	Elekta	Honoraria: Elekta
testimony  AstraZeneca Advisory Boards AstraZeneca  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy  Advisory Board  Advisory Boards AstraZeneca  None  None			Brainlab	Honoraria: Brainlab
7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy	6	Payment for expert	Novartis	Advisory Board Novartis
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy		testimony	AstraZeneca	Advisory Boards AstraZeneca
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy				
8 Patents planned, issued or pending  9 Participation on a Data None Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy	7		None	
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy  None		meetings and/or travel		
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy  None				
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy  None				
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy  None				
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy  None	8	Patents planned, issued or	None	
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy		T		
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy		-		
Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy	9	Participation on a Data	None	
10 Leadership or fiduciary role in other board, society, committee or advocacy				
in other board, society, committee or advocacy		Advisory Board		
in other board, society, committee or advocacy	10	Leadership or fiduciary role	None	
anarra maid an repaid		committee or advocacy		
group, paid or unpaid		group, paid or unpaid		
11 Stock or stock options None	11	Stock or stock options	None	
12   Receipt of equipment,	12	Receipt of equipment,	None	
materials, drugs, medical				
writing, gifts or other				
services				
13 Other financial or non- None	13		None	
financial interests		financial interests		

## Please summarize the above conflict of interest in the following box:

FM receives a Research Institutional Grant from AstraZeneca. FM serves in the advisory board of
AstraZeneca and Novartis. FM receives honoraria from AstraZeneca, Novartis, Roche, Lilly,
Elekta and Brainlab.

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

ate:10 <sup>th</sup> February 2022
our Name: Saskia Kenndoff
anuscript Title: NICOLAS, DETERRED and KEYNOTE 799: Focus on escalation of conventionally fractionated
emoradiotherapy by immune checkpoint inhibition in unresectable stage III NSCLC
anuscript number (if known): TLCR-21-950

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	None			
	testimony	None			
	,				
7	Support for attending	None			
	meetings and/or travel				
8	Patents planned, issued or	None			
	pending				
9	Participation on a Data	None			
	Safety Monitoring Board or				
10	Advisory Board	Al			
10	Leadership or fiduciary role in other board, society, committee or advocacy	None			
	group, paid or unpaid				
11	Stock or stock options	None			
12	Receipt of equipment,	None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	None			
13	financial interests	None			
Plea	Please summarize the above conflict of interest in the following box:				

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date:10 <sup>th</sup> February 2022
Your Name: Lukas Käsmann
Manuscript Title: NICOLAS, DETERRED and KEYNOTE 799: Focus on escalation of conventionally fractionated
chemoradiotherapy by immune checkpoint inhibition in unresectable stage III NSCLC
Manuscript number (if known): TLCR-21-950

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	None			
	testimony	None			
	,				
7	Support for attending	None			
	meetings and/or travel				
8	Patents planned, issued or	None			
	pending				
9	Participation on a Data	None			
	Safety Monitoring Board or				
10	Advisory Board	Al			
10	Leadership or fiduciary role in other board, society, committee or advocacy	None			
	group, paid or unpaid				
11	Stock or stock options	None			
12	Receipt of equipment,	None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	None			
13	financial interests	None			
Plea	Please summarize the above conflict of interest in the following box:				

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.